Effect of lanthanum carbonate on medical cost and laboratory values in hemodialysis patients with hyperphosphatemia

Effect of lanthanum carbonate on medical cost and laboratory values in hemodialysis patients with hyperphosphatemia - Effect of lanthanum carbonate on medical cost and laboratory values

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002058

Enrollment

150

Registered

2009-07-01

Start date

2009-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperphosphatemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The hemodialysis outpatients who can't control serum phosphate with conventional treatment.

Exclusion criteria

Exclusion criteria: 1, The patients who don't agree with this study 2, The patients who are judged inappropriate for the study by the physician

Design outcomes

Primary

Measure	Time frame
1, Change in phosphate, calcium, and parathyroid hormone before and after lanthanum carbonate treatment. 2, Change in the dose of calcium containing phosphate binder, sevelamer, vitamin D analogues, and cinacalcet. 3, Medical cost of lanthanum carbonate	—

Secondary

Measure	Time frame
Side effect of lanthanum carbonate	—

Countries

Japan

Contacts

Public ContactMasafumi Fukagawa

Kobe University Graduate School of Medicine Division of Nephrology and Kidney Center

fukagawa@med.kobe-u.ac.jp078-382-6500

Outcome results